Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Acute Myeloid Leukemia
59%
Relapsed or Refractory
59%
Overall Survival
54%
Chimeric Antigen Receptor T Cells (CAR-T)
54%
Leukemia Patients
52%
Rituximab
47%
Positron Emission Tomography-computed Tomography (PET-CT)
44%
Confidence Interval
44%
Relapsed or Refractory Acute Myeloid Leukemia
38%
Progression-free Survival
36%
Multiple Myeloma
33%
Chimeric Antigen Receptor T-cell Therapy
31%
Stem Cell Transplantation
29%
Chemotherapy
28%
Lymphoma Patients
28%
Hazard Ratio
28%
Reduced-intensity Conditioning
27%
Chronic Lymphocytic Leukemia
25%
Anti-CD19 chimeric Antigen Receptor T Cells
25%
Bendamustine
24%
Complete Remission
24%
Salvage Therapy
23%
Non-Hodgkin Lymphoma
23%
Acute Leukemia
22%
Ibrutinib
22%
Diffuse Large B-cell Lymphoma (DLBCL)
22%
Bone Marrow
22%
Transplantation
21%
Acute Lymphoblastic Leukemia
21%
Hodgkin Lymphoma
21%
CD19 chimeric Antigen Receptor T Cells
21%
Phase II Study
19%
High Risk
18%
Complete Response
18%
Engraftment
18%
Aggressive non-Hodgkin Lymphoma
18%
Helios
18%
Point-of-care
18%
Stromal Cell-derived factor-1 (SDF-1)
17%
High-dose Chemotherapy
17%
Lymphoma
17%
Graft-versus-host Disease (GvHD)
17%
Leukocytes
16%
Multivariate Analysis
16%
Leukemia
16%
Multiple Myeloma Patients
15%
Follicular Lymphoma
15%
Cyclophosphamide
15%
Aggressive B-cell Lymphoma
15%
Medicine and Dentistry
Disease
68%
Overall Survival
61%
Chimeric Antigen Receptor T-Cell
55%
Positron Emission Tomography-Computed Tomography
53%
Acute Myeloid Leukemia
52%
Non-Hodgkin Lymphoma
45%
Hodgkin's Lymphoma
45%
Progression Free Survival
41%
Rituximab
39%
Multiple Myeloma
31%
Acute Lymphoblastic Leukemia
30%
Allogeneic Stem Cell Transplantation
27%
Autologous Stem Cell Transplantation
27%
Reduced Intensity Conditioning
27%
Allogeneic Hematopoietic Stem Cell Transplantation
24%
Chimeric Antigen Receptor T-Cell Immunotherapy
23%
Salvage Therapy
22%
Bendamustine
20%
Hazard Ratio
20%
Diffuse Large B-Cell Lymphoma
20%
Large-Cell Lymphoma
20%
Chimeric Antigen Receptor
19%
B-Cell Lymphoma
18%
Hematopoietic Stem Cell Transplantation
18%
Ibrutinib
18%
Stem Cell Therapy
17%
Follicular Lymphoma
16%
High Dose Chemotherapy
16%
B-Cell Chronic Lymphocytic Leukemia
16%
Drug Megadose
15%
Cyclophosphamide
15%
Adriamycin Bleomycin Vinblastine Dacarbazine
14%
Transplantation
14%
Positron Emission Tomography
14%
B Cell
14%
Induction Chemotherapy
14%
Cancer
14%
Adverse Event
13%
Computer Assisted Tomography
13%
Multivariate Analysis
13%
Positron Emission Tomography
13%
Acute Leukemia
13%
Lymphocytic Lymphoma
13%
Ibritumomab Tiuxetan
13%
Fluorine-18
13%
Conditioning
12%
Prognostic Factor
12%
BEACOPP
12%
Fludarabine
11%
In Vitro
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
46%
Overall Survival
46%
Disease
46%
Rituximab
42%
Nonhodgkin Lymphoma
41%
Chimeric Antigen Receptor
37%
Acute Myeloid Leukemia
37%
Remission
33%
Progression Free Survival
27%
Hodgkin Disease
27%
Multiple Myeloma
27%
Bendamustine
26%
Chronic Lymphatic Leukemia
22%
Ibrutinib
22%
Infection
17%
Follicular Lymphoma
16%
B Cell Lymphoma
16%
Adverse Event
16%
Acute Lymphoblastic Leukemia
14%
Lymphocytic Lymphoma
13%
Ibritumomab Tiuxetan
13%
Mantle Cell Lymphoma
13%
Cyclophosphamide
13%
High Dose Chemotherapy
12%
Cyclin D1
12%
Diffuse Large B Cell Lymphoma
11%
COVID-19 Vaccine
10%
Placebo
10%
Neoplasm
9%
Dexamethasone
9%
Bortezomib
9%
Acute Leukemia
9%
Busulfan
9%
Yttrium 90
9%
Parsaclisib
9%
Neutropenia
8%
Vaccination Policy
7%
Prednisone
7%
Combination Therapy
7%
Monoclonal Antibody
7%
Hematologic Malignancy
7%
Acute Graft Versus Host Disease
7%
Monotherapy
7%
Cytokine Release Syndrome
7%
Event Free Survival
7%
Leukemia
7%
Disease Free Survival
6%
Syndrome
6%
Anthracycline
6%
Mycosis
6%